hematologic cancer. Cancer that begins in blood-forming tissue, such as the bone marrow, or in the cells of the immune system. Examples of hematologic cancer are leukemia, lymphoma, and multiple myeloma. Also called blood cancer.
This report aims to provide a comprehensive presentation of the global market for Hematological Cancers, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Hematological Cancers. This report contains market size and forecasts of Hematological Cancers in global, including the following market information:
Global Hematological Cancers Market Revenue, 2018-2023, 2024-2030, ($ millions)
Global top five companies in 2022 (%)
The global Hematological Cancers market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is to reach $ Million.
Pharmacological Therapies Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Hematological Cancers include Karyopharm Therapeutics, Johnson & Johnson, Roche Diagnostics A/S, AbbVie, Novartis, Kite Pharma, Celgene Corporation, Abbott Laboratories and Beckman Coulter, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Hematological Cancers companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Hematological Cancers Market, by Type, 2018-2023, 2024-2030 ($ millions)
Global Hematological Cancers Market Segment Percentages, by Type, 2022 (%)
Pharmacological Therapies
Stem Cell Transplantation
Surgery and Radiation Therapy
Anemia Treatment
Thrombosis Treatment
Neutopenia Treatment
Symptomatic treatment
Global Hematological Cancers Market, by Application, 2018-2023, 2024-2030 ($ millions)
Global Hematological Cancers Market Segment Percentages, by Application, 2022 (%)
Epidemiology
Pathophysiology of Leukemic Stem Cells
Kidney Diseases
Genetic Diseases
Other Diseases
Global Hematological Cancers Market, By Region and Country, 2018-2023, 2024-2030 ($ Millions)
Global Hematological Cancers Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Hematological Cancers revenues in global market, 2018-2023 (estimated), ($ millions)
Key companies Hematological Cancers revenues share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Karyopharm Therapeutics
Johnson & Johnson
Roche Diagnostics A/S
AbbVie
Novartis
Kite Pharma
Celgene Corporation
Abbott Laboratories
Beckman Coulter
HemoCue AB
C. R. Bard
Siemens AG
Sysmex
Mindray Medical International Limited
Bio-Rad Laboratories
The Medicine Company
Pharmacyclics
Horiba
DiagnoCure Inc.
Astellas Pharma US
Outline of Major Chapters:
Chapter 1: Introduces the definition of Hematological Cancers, market overview.
Chapter 2: Global Hematological Cancers market size in revenue.
Chapter 3: Detailed analysis of Hematological Cancers company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Hematological Cancers in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Hematological Cancers Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Hematological Cancers Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Hematological Cancers Overall Market Size
2.1 Global Hematological Cancers Market Size: 2022 VS 2030
2.2 Global Hematological Cancers Market Size, Prospects & Forecasts: 2018-2030
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Hematological Cancers Players in Global Market
3.2 Top Global Hematological Cancers Companies Ranked by Revenue
3.3 Global Hematological Cancers Revenue by Companies
3.4 Top 3 and Top 5 Hematological Cancers Companies in Global Market, by Revenue in 2022
3.5 Global Companies Hematological Cancers Product Type
3.6 Tier 1, Tier 2 and Tier 3 Hematological Cancers Players in Global Market
3.6.1 List of Global Tier 1 Hematological Cancers Companies
3.6.2 List of Global Tier 2 and Tier 3 Hematological Cancers Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type - Global Hematological Cancers Market Size Markets, 2022 & 2030
4.1.2 Pharmacological Therapies
4.1.3 Stem Cell Transplantation
4.1.4 Surgery and Radiation Therapy
4.1.5 Anemia Treatment
4.1.6 Thrombosis Treatment
4.1.7 Neutopenia Treatment
4.1.8 Symptomatic treatment
4.2 By Type - Global Hematological Cancers Revenue & Forecasts
4.2.1 By Type - Global Hematological Cancers Revenue, 2018-2023
4.2.2 By Type - Global Hematological Cancers Revenue, 2024-2030
4.2.3 By Type - Global Hematological Cancers Revenue Market Share, 2018-2030
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Hematological Cancers Market Size, 2022 & 2030
5.1.2 Epidemiology
5.1.3 Pathophysiology of Leukemic Stem Cells
5.1.4 Kidney Diseases
5.1.5 Genetic Diseases
5.1.6 Other Diseases
5.2 By Application - Global Hematological Cancers Revenue & Forecasts
5.2.1 By Application - Global Hematological Cancers Revenue, 2018-2023
5.2.2 By Application - Global Hematological Cancers Revenue, 2024-2030
5.2.3 By Application - Global Hematological Cancers Revenue Market Share, 2018-2030
6 Sights by Region
6.1 By Region - Global Hematological Cancers Market Size, 2022 & 2030
6.2 By Region - Global Hematological Cancers Revenue & Forecasts
6.2.1 By Region - Global Hematological Cancers Revenue, 2018-2023
6.2.2 By Region - Global Hematological Cancers Revenue, 2024-2030
6.2.3 By Region - Global Hematological Cancers Revenue Market Share, 2018-2030
6.3 North America
6.3.1 By Country - North America Hematological Cancers Revenue, 2018-2030
6.3.2 US Hematological Cancers Market Size, 2018-2030
6.3.3 Canada Hematological Cancers Market Size, 2018-2030
6.3.4 Mexico Hematological Cancers Market Size, 2018-2030
6.4 Europe
6.4.1 By Country - Europe Hematological Cancers Revenue, 2018-2030
6.4.2 Germany Hematological Cancers Market Size, 2018-2030
6.4.3 France Hematological Cancers Market Size, 2018-2030
6.4.4 U.K. Hematological Cancers Market Size, 2018-2030
6.4.5 Italy Hematological Cancers Market Size, 2018-2030
6.4.6 Russia Hematological Cancers Market Size, 2018-2030
6.4.7 Nordic Countries Hematological Cancers Market Size, 2018-2030
6.4.8 Benelux Hematological Cancers Market Size, 2018-2030
6.5 Asia
6.5.1 By Region - Asia Hematological Cancers Revenue, 2018-2030
6.5.2 China Hematological Cancers Market Size, 2018-2030
6.5.3 Japan Hematological Cancers Market Size, 2018-2030
6.5.4 South Korea Hematological Cancers Market Size, 2018-2030
6.5.5 Southeast Asia Hematological Cancers Market Size, 2018-2030
6.5.6 India Hematological Cancers Market Size, 2018-2030
6.6 South America
6.6.1 By Country - South America Hematological Cancers Revenue, 2018-2030
6.6.2 Brazil Hematological Cancers Market Size, 2018-2030
6.6.3 Argentina Hematological Cancers Market Size, 2018-2030
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Hematological Cancers Revenue, 2018-2030
6.7.2 Turkey Hematological Cancers Market Size, 2018-2030
6.7.3 Israel Hematological Cancers Market Size, 2018-2030
6.7.4 Saudi Arabia Hematological Cancers Market Size, 2018-2030
6.7.5 UAE Hematological Cancers Market Size, 2018-2030
7 Hematological Cancers Companies Profiles
7.1 Karyopharm Therapeutics
7.1.1 Karyopharm Therapeutics Company Summary
7.1.2 Karyopharm Therapeutics Business Overview
7.1.3 Karyopharm Therapeutics Hematological Cancers Major Product Offerings
7.1.4 Karyopharm Therapeutics Hematological Cancers Revenue in Global Market (2018-2023)
7.1.5 Karyopharm Therapeutics Key News & Latest Developments
7.2 Johnson & Johnson
7.2.1 Johnson & Johnson Company Summary
7.2.2 Johnson & Johnson Business Overview
7.2.3 Johnson & Johnson Hematological Cancers Major Product Offerings
7.2.4 Johnson & Johnson Hematological Cancers Revenue in Global Market (2018-2023)
7.2.5 Johnson & Johnson Key News & Latest Developments
7.3 Roche Diagnostics A/S
7.3.1 Roche Diagnostics A/S Company Summary
7.3.2 Roche Diagnostics A/S Business Overview
7.3.3 Roche Diagnostics A/S Hematological Cancers Major Product Offerings
7.3.4 Roche Diagnostics A/S Hematological Cancers Revenue in Global Market (2018-2023)
7.3.5 Roche Diagnostics A/S Key News & Latest Developments
7.4 AbbVie
7.4.1 AbbVie Company Summary
7.4.2 AbbVie Business Overview
7.4.3 AbbVie Hematological Cancers Major Product Offerings
7.4.4 AbbVie Hematological Cancers Revenue in Global Market (2018-2023)
7.4.5 AbbVie Key News & Latest Developments
7.5 Novartis
7.5.1 Novartis Company Summary
7.5.2 Novartis Business Overview
7.5.3 Novartis Hematological Cancers Major Product Offerings
7.5.4 Novartis Hematological Cancers Revenue in Global Market (2018-2023)
7.5.5 Novartis Key News & Latest Developments
7.6 Kite Pharma
7.6.1 Kite Pharma Company Summary
7.6.2 Kite Pharma Business Overview
7.6.3 Kite Pharma Hematological Cancers Major Product Offerings
7.6.4 Kite Pharma Hematological Cancers Revenue in Global Market (2018-2023)
7.6.5 Kite Pharma Key News & Latest Developments
7.7 Celgene Corporation
7.7.1 Celgene Corporation Company Summary
7.7.2 Celgene Corporation Business Overview
7.7.3 Celgene Corporation Hematological Cancers Major Product Offerings
7.7.4 Celgene Corporation Hematological Cancers Revenue in Global Market (2018-2023)
7.7.5 Celgene Corporation Key News & Latest Developments
7.8 Abbott Laboratories
7.8.1 Abbott Laboratories Company Summary
7.8.2 Abbott Laboratories Business Overview
7.8.3 Abbott Laboratories Hematological Cancers Major Product Offerings
7.8.4 Abbott Laboratories Hematological Cancers Revenue in Global Market (2018-2023)
7.8.5 Abbott Laboratories Key News & Latest Developments
7.9 Beckman Coulter
7.9.1 Beckman Coulter Company Summary
7.9.2 Beckman Coulter Business Overview
7.9.3 Beckman Coulter Hematological Cancers Major Product Offerings
7.9.4 Beckman Coulter Hematological Cancers Revenue in Global Market (2018-2023)
7.9.5 Beckman Coulter Key News & Latest Developments
7.10 HemoCue AB
7.10.1 HemoCue AB Company Summary
7.10.2 HemoCue AB Business Overview
7.10.3 HemoCue AB Hematological Cancers Major Product Offerings
7.10.4 HemoCue AB Hematological Cancers Revenue in Global Market (2018-2023)
7.10.5 HemoCue AB Key News & Latest Developments
7.11 C. R. Bard
7.11.1 C. R. Bard Company Summary
7.11.2 C. R. Bard Business Overview
7.11.3 C. R. Bard Hematological Cancers Major Product Offerings
7.11.4 C. R. Bard Hematological Cancers Revenue in Global Market (2018-2023)
7.11.5 C. R. Bard Key News & Latest Developments
7.12 Siemens AG
7.12.1 Siemens AG Company Summary
7.12.2 Siemens AG Business Overview
7.12.3 Siemens AG Hematological Cancers Major Product Offerings
7.12.4 Siemens AG Hematological Cancers Revenue in Global Market (2018-2023)
7.12.5 Siemens AG Key News & Latest Developments
7.13 Sysmex
7.13.1 Sysmex Company Summary
7.13.2 Sysmex Business Overview
7.13.3 Sysmex Hematological Cancers Major Product Offerings
7.13.4 Sysmex Hematological Cancers Revenue in Global Market (2018-2023)
7.13.5 Sysmex Key News & Latest Developments
7.14 Mindray Medical International Limited
7.14.1 Mindray Medical International Limited Company Summary
7.14.2 Mindray Medical International Limited Business Overview
7.14.3 Mindray Medical International Limited Hematological Cancers Major Product Offerings
7.14.4 Mindray Medical International Limited Hematological Cancers Revenue in Global Market (2018-2023)
7.14.5 Mindray Medical International Limited Key News & Latest Developments
7.15 Bio-Rad Laboratories
7.15.1 Bio-Rad Laboratories Company Summary
7.15.2 Bio-Rad Laboratories Business Overview
7.15.3 Bio-Rad Laboratories Hematological Cancers Major Product Offerings
7.15.4 Bio-Rad Laboratories Hematological Cancers Revenue in Global Market (2018-2023)
7.15.5 Bio-Rad Laboratories Key News & Latest Developments
7.16 The Medicine Company
7.16.1 The Medicine Company Company Summary
7.16.2 The Medicine Company Business Overview
7.16.3 The Medicine Company Hematological Cancers Major Product Offerings
7.16.4 The Medicine Company Hematological Cancers Revenue in Global Market (2018-2023)
7.16.5 The Medicine Company Key News & Latest Developments
7.17 Pharmacyclics
7.17.1 Pharmacyclics Company Summary
7.17.2 Pharmacyclics Business Overview
7.17.3 Pharmacyclics Hematological Cancers Major Product Offerings
7.17.4 Pharmacyclics Hematological Cancers Revenue in Global Market (2018-2023)
7.17.5 Pharmacyclics Key News & Latest Developments
7.18 Horiba
7.18.1 Horiba Company Summary
7.18.2 Horiba Business Overview
7.18.3 Horiba Hematological Cancers Major Product Offerings
7.18.4 Horiba Hematological Cancers Revenue in Global Market (2018-2023)
7.18.5 Horiba Key News & Latest Developments
7.19 DiagnoCure Inc.
7.19.1 DiagnoCure Inc. Company Summary
7.19.2 DiagnoCure Inc. Business Overview
7.19.3 DiagnoCure Inc. Hematological Cancers Major Product Offerings
7.19.4 DiagnoCure Inc. Hematological Cancers Revenue in Global Market (2018-2023)
7.19.5 DiagnoCure Inc. Key News & Latest Developments
7.20 Astellas Pharma US
7.20.1 Astellas Pharma US Company Summary
7.20.2 Astellas Pharma US Business Overview
7.20.3 Astellas Pharma US Hematological Cancers Major Product Offerings
7.20.4 Astellas Pharma US Hematological Cancers Revenue in Global Market (2018-2023)
7.20.5 Astellas Pharma US Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Hematological Cancers Market Opportunities & Trends in Global Market
Table 2. Hematological Cancers Market Drivers in Global Market
Table 3. Hematological Cancers Market Restraints in Global Market
Table 4. Key Players of Hematological Cancers in Global Market
Table 5. Top Hematological Cancers Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Hematological Cancers Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Hematological Cancers Revenue Share by Companies, 2018-2023
Table 8. Global Companies Hematological Cancers Product Type
Table 9. List of Global Tier 1 Hematological Cancers Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Hematological Cancers Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type ? Global Hematological Cancers Revenue, (US$, Mn), 2022 & 2030
Table 12. By Type - Hematological Cancers Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Hematological Cancers Revenue in Global (US$, Mn), 2024-2030
Table 14. By Application ? Global Hematological Cancers Revenue, (US$, Mn), 2022 & 2030
Table 15. By Application - Hematological Cancers Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Hematological Cancers Revenue in Global (US$, Mn), 2024-2030
Table 17. By Region ? Global Hematological Cancers Revenue, (US$, Mn), 2022 & 2030
Table 18. By Region - Global Hematological Cancers Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Hematological Cancers Revenue (US$, Mn), 2024-2030
Table 20. By Country - North America Hematological Cancers Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Hematological Cancers Revenue, (US$, Mn), 2024-2030
Table 22. By Country - Europe Hematological Cancers Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Hematological Cancers Revenue, (US$, Mn), 2024-2030
Table 24. By Region - Asia Hematological Cancers Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Hematological Cancers Revenue, (US$, Mn), 2024-2030
Table 26. By Country - South America Hematological Cancers Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Hematological Cancers Revenue, (US$, Mn), 2024-2030
Table 28. By Country - Middle East & Africa Hematological Cancers Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Hematological Cancers Revenue, (US$, Mn), 2024-2030
Table 30. Karyopharm Therapeutics Company Summary
Table 31. Karyopharm Therapeutics Hematological Cancers Product Offerings
Table 32. Karyopharm Therapeutics Hematological Cancers Revenue (US$, Mn) & (2018-2023)
Table 33. Karyopharm Therapeutics Key News & Latest Developments
Table 34. Johnson & Johnson Company Summary
Table 35. Johnson & Johnson Hematological Cancers Product Offerings
Table 36. Johnson & Johnson Hematological Cancers Revenue (US$, Mn) & (2018-2023)
Table 37. Johnson & Johnson Key News & Latest Developments
Table 38. Roche Diagnostics A/S Company Summary
Table 39. Roche Diagnostics A/S Hematological Cancers Product Offerings
Table 40. Roche Diagnostics A/S Hematological Cancers Revenue (US$, Mn) & (2018-2023)
Table 41. Roche Diagnostics A/S Key News & Latest Developments
Table 42. AbbVie Company Summary
Table 43. AbbVie Hematological Cancers Product Offerings
Table 44. AbbVie Hematological Cancers Revenue (US$, Mn) & (2018-2023)
Table 45. AbbVie Key News & Latest Developments
Table 46. Novartis Company Summary
Table 47. Novartis Hematological Cancers Product Offerings
Table 48. Novartis Hematological Cancers Revenue (US$, Mn) & (2018-2023)
Table 49. Novartis Key News & Latest Developments
Table 50. Kite Pharma Company Summary
Table 51. Kite Pharma Hematological Cancers Product Offerings
Table 52. Kite Pharma Hematological Cancers Revenue (US$, Mn) & (2018-2023)
Table 53. Kite Pharma Key News & Latest Developments
Table 54. Celgene Corporation Company Summary
Table 55. Celgene Corporation Hematological Cancers Product Offerings
Table 56. Celgene Corporation Hematological Cancers Revenue (US$, Mn) & (2018-2023)
Table 57. Celgene Corporation Key News & Latest Developments
Table 58. Abbott Laboratories Company Summary
Table 59. Abbott Laboratories Hematological Cancers Product Offerings
Table 60. Abbott Laboratories Hematological Cancers Revenue (US$, Mn) & (2018-2023)
Table 61. Abbott Laboratories Key News & Latest Developments
Table 62. Beckman Coulter Company Summary
Table 63. Beckman Coulter Hematological Cancers Product Offerings
Table 64. Beckman Coulter Hematological Cancers Revenue (US$, Mn) & (2018-2023)
Table 65. Beckman Coulter Key News & Latest Developments
Table 66. HemoCue AB Company Summary
Table 67. HemoCue AB Hematological Cancers Product Offerings
Table 68. HemoCue AB Hematological Cancers Revenue (US$, Mn) & (2018-2023)
Table 69. HemoCue AB Key News & Latest Developments
Table 70. C. R. Bard Company Summary
Table 71. C. R. Bard Hematological Cancers Product Offerings
Table 72. C. R. Bard Hematological Cancers Revenue (US$, Mn) & (2018-2023)
Table 73. C. R. Bard Key News & Latest Developments
Table 74. Siemens AG Company Summary
Table 75. Siemens AG Hematological Cancers Product Offerings
Table 76. Siemens AG Hematological Cancers Revenue (US$, Mn) & (2018-2023)
Table 77. Siemens AG Key News & Latest Developments
Table 78. Sysmex Company Summary
Table 79. Sysmex Hematological Cancers Product Offerings
Table 80. Sysmex Hematological Cancers Revenue (US$, Mn) & (2018-2023)
Table 81. Sysmex Key News & Latest Developments
Table 82. Mindray Medical International Limited Company Summary
Table 83. Mindray Medical International Limited Hematological Cancers Product Offerings
Table 84. Mindray Medical International Limited Hematological Cancers Revenue (US$, Mn) & (2018-2023)
Table 85. Mindray Medical International Limited Key News & Latest Developments
Table 86. Bio-Rad Laboratories Company Summary
Table 87. Bio-Rad Laboratories Hematological Cancers Product Offerings
Table 88. Bio-Rad Laboratories Hematological Cancers Revenue (US$, Mn) & (2018-2023)
Table 89. Bio-Rad Laboratories Key News & Latest Developments
Table 90. The Medicine Company Company Summary
Table 91. The Medicine Company Hematological Cancers Product Offerings
Table 92. The Medicine Company Hematological Cancers Revenue (US$, Mn) & (2018-2023)
Table 93. The Medicine Company Key News & Latest Developments
Table 94. Pharmacyclics Company Summary
Table 95. Pharmacyclics Hematological Cancers Product Offerings
Table 96. Pharmacyclics Hematological Cancers Revenue (US$, Mn) & (2018-2023)
Table 97. Pharmacyclics Key News & Latest Developments
Table 98. Horiba Company Summary
Table 99. Horiba Hematological Cancers Product Offerings
Table 100. Horiba Hematological Cancers Revenue (US$, Mn) & (2018-2023)
Table 101. Horiba Key News & Latest Developments
Table 102. DiagnoCure Inc. Company Summary
Table 103. DiagnoCure Inc. Hematological Cancers Product Offerings
Table 104. DiagnoCure Inc. Hematological Cancers Revenue (US$, Mn) & (2018-2023)
Table 105. DiagnoCure Inc. Key News & Latest Developments
Table 106. Astellas Pharma US Company Summary
Table 107. Astellas Pharma US Hematological Cancers Product Offerings
Table 108. Astellas Pharma US Hematological Cancers Revenue (US$, Mn) & (2018-2023)
Table 109. Astellas Pharma US Key News & Latest Developments
List of Figures
Figure 1. Hematological Cancers Segment by Type in 2022
Figure 2. Hematological Cancers Segment by Application in 2022
Figure 3. Global Hematological Cancers Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Hematological Cancers Market Size: 2022 VS 2030 (US$, Mn)
Figure 6. Global Hematological Cancers Revenue, 2018-2030 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Hematological Cancers Revenue in 2022
Figure 8. By Type - Global Hematological Cancers Revenue Market Share, 2018-2030
Figure 9. By Application - Global Hematological Cancers Revenue Market Share, 2018-2030
Figure 10. By Type - Global Hematological Cancers Revenue, (US$, Mn), 2022 & 2030
Figure 11. By Type - Global Hematological Cancers Revenue Market Share, 2018-2030
Figure 12. By Application - Global Hematological Cancers Revenue, (US$, Mn), 2022 & 2030
Figure 13. By Application - Global Hematological Cancers Revenue Market Share, 2018-2030
Figure 14. By Region - Global Hematological Cancers Revenue Market Share, 2018-2030
Figure 15. By Country - North America Hematological Cancers Revenue Market Share, 2018-2030
Figure 16. US Hematological Cancers Revenue, (US$, Mn), 2018-2030
Figure 17. Canada Hematological Cancers Revenue, (US$, Mn), 2018-2030
Figure 18. Mexico Hematological Cancers Revenue, (US$, Mn), 2018-2030
Figure 19. By Country - Europe Hematological Cancers Revenue Market Share, 2018-2030
Figure 20. Germany Hematological Cancers Revenue, (US$, Mn), 2018-2030
Figure 21. France Hematological Cancers Revenue, (US$, Mn), 2018-2030
Figure 22. U.K. Hematological Cancers Revenue, (US$, Mn), 2018-2030
Figure 23. Italy Hematological Cancers Revenue, (US$, Mn), 2018-2030
Figure 24. Russia Hematological Cancers Revenue, (US$, Mn), 2018-2030
Figure 25. Nordic Countries Hematological Cancers Revenue, (US$, Mn), 2018-2030
Figure 26. Benelux Hematological Cancers Revenue, (US$, Mn), 2018-2030
Figure 27. By Region - Asia Hematological Cancers Revenue Market Share, 2018-2030
Figure 28. China Hematological Cancers Revenue, (US$, Mn), 2018-2030
Figure 29. Japan Hematological Cancers Revenue, (US$, Mn), 2018-2030
Figure 30. South Korea Hematological Cancers Revenue, (US$, Mn), 2018-2030
Figure 31. Southeast Asia Hematological Cancers Revenue, (US$, Mn), 2018-2030
Figure 32. India Hematological Cancers Revenue, (US$, Mn), 2018-2030
Figure 33. By Country - South America Hematological Cancers Revenue Market Share, 2018-2030
Figure 34. Brazil Hematological Cancers Revenue, (US$, Mn), 2018-2030
Figure 35. Argentina Hematological Cancers Revenue, (US$, Mn), 2018-2030
Figure 36. By Country - Middle East & Africa Hematological Cancers Revenue Market Share, 2018-2030
Figure 37. Turkey Hematological Cancers Revenue, (US$, Mn), 2018-2030
Figure 38. Israel Hematological Cancers Revenue, (US$, Mn), 2018-2030
Figure 39. Saudi Arabia Hematological Cancers Revenue, (US$, Mn), 2018-2030
Figure 40. UAE Hematological Cancers Revenue, (US$, Mn), 2018-2030
Figure 41. Karyopharm Therapeutics Hematological Cancers Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Johnson & Johnson Hematological Cancers Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Roche Diagnostics A/S Hematological Cancers Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. AbbVie Hematological Cancers Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Novartis Hematological Cancers Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Kite Pharma Hematological Cancers Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Celgene Corporation Hematological Cancers Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Abbott Laboratories Hematological Cancers Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Beckman Coulter Hematological Cancers Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. HemoCue AB Hematological Cancers Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. C. R. Bard Hematological Cancers Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 52. Siemens AG Hematological Cancers Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 53. Sysmex Hematological Cancers Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 54. Mindray Medical International Limited Hematological Cancers Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 55. Bio-Rad Laboratories Hematological Cancers Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 56. The Medicine Company Hematological Cancers Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 57. Pharmacyclics Hematological Cancers Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 58. Horiba Hematological Cancers Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 59. DiagnoCure Inc. Hematological Cancers Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 60. Astellas Pharma US Hematological Cancers Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
